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TReasons for inability of clopidogrel
to inhibit platelet aggregation early
after coronary artery bypass surgery
To the Editor:
Clopidogrel administration for platelet in-
hibition after coronary artery surgery and
interventional cardiology is currently a
topic of much-deserved attention and de-
bate. I read with interest the recent article
in the Journal by Lim and colleagues.1 On
the basis of the results of an interim anal-
ysis of their prospective, double-blind, ran-
domized, controlled trial to compare the
efficacy of clopidogrel and aspirin as anti-
platelet agents, Lim and colleagues con-
clude that clopidogrel, unlike aspirin, did
not inhibit platelet aggregation in the first 5
postoperative days and therefore should not
be used as a sole antiplatelet agent early
after coronary surgery. According to the
authors, the ineffectiveness of clopidogrel
was an “unexpected” finding. However,
plenty of evidence is available from pub-
lished studies to suggest a logical explana-
tion for this unexpected finding.
Clopidogrel is a pro-drug, which is con-
verted to an active, unstable drug by cyto-
chrome P450 (CYP). The active drug irre-
versibly blocks 1 specific platelet: adenosine
5’-diphosphate receptor (P2Y12). It was re-
cently suggested that the most abundant hu-
man CYP isoform, 3A4, activates clopi-
dogrel.2 Certain lipophilic statins (ie,
simvastatin, atorvastatin, and lovastatin),
which are substrates of the CYP3A4 isoform,
competitively inhibit the metabolic activation
of clopidogrel. As a result, the relative clopi-
dogrel-induced platelet inhibition is dimin-
ished, especially if administered in a low
dose.3 Furthermore, clopidogrel administra-
tion results in interindividual variability in
platelet inhibition. This variable platelet inhi-
bition response to clopidogrel has been rec-
ognized by all who have tested clopidogrel
efficacy by platelet aggregometry and corre-
lates with CYP3A4 metabolic activity.4 In
addition, it is extremely important to remem-
ber that platelet inhibition by clopidogrel is
dose-related up to a dose of 400 mg and that
he Journal of Thoracic and Cardiovascularinhibition at a higher dose remains stable
from 2 to 72 hours.5
A closer look at the study by Lim and
colleagues1 clearly reveals that all of these
confounding factors are present and that
they influence the results of their interim
analysis. In my opinion, the conclusion of
this study would be different if a larger
dose of clopidogrel were used and nonre-
sponders (10%) and low responders
(20%), as well as those on statins, were
excluded.
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Letters to the
Editor
Reply to the Editor:
The opinion on the interaction between
statins and clopidogrel is still subject to
fierce debate.1,2 However, excluding sub-
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